HRP20120573T1 - Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino) benzamida - Google Patents

Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino) benzamida Download PDF

Info

Publication number: HRP20120573T1
Authority: HR; Croatia
Prior art keywords: methyl; crystalline form; substantially pure; ylamino; imidazol
Prior art date: 2005-07-20

Application number

HRP20120573TT

Other languages

English (en)

Croatian (hr)

Inventor

W. Manley Paul

Shieh Wen-Chung

Allen Sutton Paul

H. Karpinski Piotr

Wu Raeann

Monnier St�phanie

Brozio J�rg

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-20

Filing date

2006-07-18

Publication date

2012-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-07-18 Application filed by Novartis Ag filed Critical Novartis Ag

2012-08-31 Publication of HRP20120573T1 publication Critical patent/HRP20120573T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

HRP20120573TT 2005-07-20 2006-07-18 Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino) benzamida HRP20120573T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US70140505P	2005-07-20	2005-07-20
US71621405P	2005-09-12	2005-09-12
PCT/US2006/027875 WO2007015870A2 (en)	2005-07-20	2006-07-18	Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (1)

Publication Number	Publication Date
HRP20120573T1 true HRP20120573T1 (hr)	2012-08-31

Family

ID=37451227

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HRP20120573TT HRP20120573T1 (hr)	2005-07-20	2006-07-18	Kristalni oblici 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino) benzamida
HRP20170634TT HRP20170634T4 (hr)	2005-07-20	2017-04-24	Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HRP20170634TT HRP20170634T4 (hr)	2005-07-20	2017-04-24	Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida

Country Status (42)

Country	Link
US (4)	US8343984B2 (sr)
EP (5)	EP2543665A3 (sr)
JP (3)	JP5289948B2 (sr)
KR (3)	KR20130077915A (sr)
CN (2)	CN103804356A (sr)
AR (1)	AR054846A1 (sr)
AU (3)	AU2006276204A1 (sr)
BR (1)	BRPI0613615B1 (sr)
CA (1)	CA2614334C (sr)
CR (1)	CR9657A (sr)
CU (1)	CU23916B1 (sr)
CY (2)	CY1113076T1 (sr)
DK (2)	DK2284167T4 (sr)
EA (2)	EA013464B1 (sr)
EC (1)	ECSP088119A (sr)
ES (3)	ES2386974T3 (sr)
GE (1)	GEP20115302B (sr)
GT (1)	GT200600315A (sr)
HN (1)	HN2008000311A (sr)
HR (2)	HRP20120573T1 (sr)
HU (1)	HUE031791T2 (sr)
IL (2)	IL188189A0 (sr)
JO (1)	JO3308B1 (sr)
LT (1)	LT2284167T (sr)
MA (1)	MA29626B1 (sr)
MX (1)	MX2008000899A (sr)
MY (1)	MY148554A (sr)
NI (1)	NI200800017A (sr)
NO (1)	NO341930B1 (sr)
NZ (1)	NZ564409A (sr)
PE (1)	PE20070214A1 (sr)
PH (1)	PH12013501590A1 (sr)
PL (2)	PL1912973T3 (sr)
PT (2)	PT1912973E (sr)
RS (1)	RS55929B2 (sr)
SG (1)	SG163620A1 (sr)
SI (2)	SI2284167T2 (sr)
SM (1)	SMP200800011B (sr)
TN (1)	TNSN08029A1 (sr)
TW (1)	TWI406661B (sr)
UA (1)	UA94234C2 (sr)
WO (1)	WO2007015870A2 (sr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200600315A (es)	2005-07-20	2007-03-19		Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) *	2005-07-20	2007-04-02		Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
MX2008012903A (es) *	2006-04-07	2008-10-13	Novartis Ag	Uso de inhibidores de c-src en combinacion con un compuesto de pirimidilaminobenzamida para el tratamiento de la leucemia.
EP1923053A1 (en)	2006-09-27	2008-05-21	Novartis AG	Pharmaceutical compositions comprising nilotinib or its salt
ES2459877T3 (es) *	2007-12-21	2014-05-12	Novartis Ag	Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica
WO2010009402A2 (en) *	2008-07-17	2010-01-21	Teva Pharmaceutical Industries Ltd.	Nilotinib intermediates and preparation thereof
US8227477B2 (en) *	2008-11-05	2012-07-24	Greta Sterimbaum	Nilotinib HCl crystalline forms
EP2186514B1 (en)	2008-11-14	2016-06-29	Kinki University	Treatment of Malignant Peripheral Nerve Sheath Tumors
RU2011140404A (ru)	2009-03-06	2013-04-20	Новартис Аг	Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)
TW201102068A (en)	2009-06-02	2011-01-16	Novartis Ag	Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
KR20120099650A (ko)	2009-10-23	2012-09-11	노파르티스 아게	Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
JO3634B1 (ar)	2009-11-17	2020-08-27	Novartis Ag	طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (sr) *	2010-01-15	2016-09-02
JP2013525296A (ja)	2010-04-16	2013-06-20	ノバルティスアーゲー	内分泌療法抵抗性乳癌の処置
EP2382976A1 (en)	2010-04-30	2011-11-02	Hiroshima University	Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
ES2555263T3 (es)	2010-06-21	2015-12-30	Teva Pharmaceutical Industries Ltd.	Sales de Nilotinib y formas cristalinas de las mismas
CN102453024B (zh) *	2010-10-27	2014-09-03	浙江九洲药业股份有限公司	一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (en) *	2010-11-26	2012-05-31	Hetero Research Foundation	Novel polymorph of nilotinib hydrochloride
AR086913A1 (es)	2011-06-14	2014-01-29	Novartis Ag	4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
WO2013063000A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
JP6275645B2 (ja)	2011-11-14	2018-02-07	ノバルティスアーゲー	４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤
EP2626355B1 (en) *	2012-02-09	2016-02-03	Natco Pharma Limited	Process for the preparation of nilotinib hydrochloride
WO2013120852A1 (en)	2012-02-13	2013-08-22	Grindeks, A Joint Stock Company	Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en)	2012-02-15	2015-06-23	Natco Pharma Limited	Process for the preparation of Nilotinib
RU2015104537A (ru)	2012-07-11	2016-08-27	Новартис Аг	Способы лечения стромальных опухолей желудочно-кишечного тракта
EP2906554A4 (en) *	2012-10-15	2016-06-29	Apotex Inc	SOLID FORMS OF NILOTINIB HYDROCHLORIDE
AU2013333953B2 (en) *	2012-10-19	2017-08-31	Basf Se	Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
AU2014220354B2 (en) *	2013-02-21	2018-02-01	Pfizer Inc.	Solid forms of a selective CDK4/6 inhibitor
EP2792360A1 (en)	2013-04-18	2014-10-22	IP Gesellschaft für Management mbH	(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2014174456A2 (en) *	2013-04-24	2014-10-30	Dr. Reddys Laboratories Limited	Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) *	2013-11-28	2021-08-20	Общество с ограниченной ответственностью "Мамонт Фарм"	Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en)	2013-12-16	2015-06-25	Ranbaxy Laboratories Limited	Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en)	2014-08-08	2018-03-27	Dr. Reddy's Laboratories Limited	Process for the preparation of polymorphic forms of nilotinib hydrochloride
MX2017004770A (es) *	2014-10-16	2017-07-26	Apotex Inc	Formas solidas del clorhidrato de nilotinib.
SI3408264T1 (sl)	2016-01-26	2020-07-31	Farma Grs, D.O.O.	Nilotinibijev dinitrat (V) in njegove kristalne oblike
WO2017149550A1 (en) *	2016-03-02	2017-09-08	Msn Laboratories Private Limited	Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
HUE050890T2 (hu)	2016-03-14	2021-01-28	Pliva Hrvatska D O O	Nilotinib sók szilárd halmazállapotú formái
CN106496193A (zh) *	2016-09-13	2017-03-15	福格森（武汉）生物科技股份有限公司	一种高纯度尼罗替尼的制备方法
EP3404025B1 (en)	2017-05-16	2019-12-04	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs)	2017-12-20	2019-07-03	Zentiva, K.S.	Léková forma obsahující krystalický nilotinib
CN120305263A (zh)	2018-06-15	2025-07-15	汉达癌症医药责任有限公司	卡博替尼的盐类于制备治疗癌症的剂型的用途
JP2020007240A (ja) *	2018-07-04	2020-01-16	住友化学株式会社	ベンズアミド化合物の製造方法
WO2020095187A1 (en) *	2018-11-05	2020-05-14	Laurus Labs Limited	Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
EP4096791A1 (en)	2020-01-31	2022-12-07	Nanocopoeia LLC	Amorphous nilotinib microparticles and uses thereof
IL297776A (en)	2020-04-30	2022-12-01	Nanocopoeia Llc	Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN114133378B (zh) *	2020-09-04	2023-08-15	成都苑东生物制药股份有限公司	一种盐酸尼洛替尼共晶及其制备方法
MX2023003556A (es)	2020-09-29	2023-06-13	Shenzhen Pharmacin Co Ltd	Composiciones farmaceuticas.
MX2023015480A (es)	2021-06-19	2024-01-19	Helm Ag	Composicion granulada que comprende nilotinib.
EP4122452A1 (en)	2021-07-23	2023-01-25	KRKA, d.d., Novo mesto	Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) *	2021-09-27	2021-12-14	南京海润医药有限公司	一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en)	2022-04-11	2023-10-18	Lotus Pharmaceutical Co., Ltd.	Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) *	2023-01-05	2025-03-25	浙江工业大学	两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US701406A (en)	1901-07-16	1902-06-03	Thomas K Jones	Cut-off-valve mechanism.
US701405A (en)	1902-02-17	1902-06-03	Archibald White Maconochie	Ejecting device for stamping-machines.
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0325031D0 (en) *	2003-10-27	2003-12-03	Novartis Ag	Organic compounds
PT1686997E (pt) *	2003-11-18	2009-07-17	Novartis Ag	Inibidores da forma mutante de kit
GT200600315A (es)	2005-07-20	2007-03-19		Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es)	2005-07-20	2007-04-02		Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

2006
- 2006-07-14 GT GT200600315A patent/GT200600315A/es unknown
- 2006-07-18 EP EP12160544.8A patent/EP2543665A3/en not_active Withdrawn
- 2006-07-18 PT PT06800109T patent/PT1912973E/pt unknown
- 2006-07-18 AU AU2006276204A patent/AU2006276204A1/en not_active Abandoned
- 2006-07-18 WO PCT/US2006/027875 patent/WO2007015870A2/en not_active Ceased
- 2006-07-18 HU HUE10173956A patent/HUE031791T2/en unknown
- 2006-07-18 NI NI200800017A patent/NI200800017A/es unknown
- 2006-07-18 UA UAA200800629A patent/UA94234C2/uk unknown
- 2006-07-18 DK DK10173956.3T patent/DK2284167T4/da active
- 2006-07-18 SI SI200632162T patent/SI2284167T2/sl unknown
- 2006-07-18 KR KR1020137016680A patent/KR20130077915A/ko not_active Ceased
- 2006-07-18 PL PL06800109T patent/PL1912973T3/pl unknown
- 2006-07-18 MY MYPI20063404A patent/MY148554A/en unknown
- 2006-07-18 EP EP06800109A patent/EP1912973B1/en not_active Revoked
- 2006-07-18 BR BRPI0613615-0A patent/BRPI0613615B1/pt active IP Right Grant
- 2006-07-18 PT PT101739563T patent/PT2284167T/pt unknown
- 2006-07-18 KR KR1020137016681A patent/KR20130085444A/ko not_active Ceased
- 2006-07-18 JP JP2008522899A patent/JP5289948B2/ja active Active
- 2006-07-18 DK DK06800109.8T patent/DK1912973T3/da active
- 2006-07-18 PL PL10173956T patent/PL2284167T5/pl unknown
- 2006-07-18 SM SM200800011T patent/SMP200800011B/it unknown
- 2006-07-18 ES ES06800109T patent/ES2386974T3/es active Active
- 2006-07-18 GE GEAP200610480A patent/GEP20115302B/en unknown
- 2006-07-18 CN CN201310349258.8A patent/CN103804356A/zh active Pending
- 2006-07-18 SI SI200631365T patent/SI1912973T1/sl unknown
- 2006-07-18 EP EP10173956.3A patent/EP2284167B2/en active Active
- 2006-07-18 ES ES10173956T patent/ES2623608T5/es active Active
- 2006-07-18 LT LTEP10173956.3T patent/LT2284167T/lt unknown
- 2006-07-18 EP EP10173964A patent/EP2284168A3/en not_active Withdrawn
- 2006-07-18 EP EP12160493.8A patent/EP2535337B1/en active Active
- 2006-07-18 AR ARP060103070A patent/AR054846A1/es unknown
- 2006-07-18 CA CA2614334A patent/CA2614334C/en active Active
- 2006-07-18 EA EA200800201A patent/EA013464B1/ru not_active IP Right Cessation
- 2006-07-18 NZ NZ564409A patent/NZ564409A/en unknown
- 2006-07-18 ES ES12160493.8T patent/ES2648288T3/es active Active
- 2006-07-18 SG SG201005165-4A patent/SG163620A1/en unknown
- 2006-07-18 CN CN2011102583896A patent/CN102358736A/zh active Pending
- 2006-07-18 RS RS20170384A patent/RS55929B2/sr unknown
- 2006-07-18 EA EA201000145A patent/EA016856B1/ru not_active IP Right Cessation
- 2006-07-18 HR HRP20120573TT patent/HRP20120573T1/hr unknown
- 2006-07-18 US US11/995,906 patent/US8343984B2/en active Active
- 2006-07-18 KR KR1020087001457A patent/KR101651288B1/ko active Active
- 2006-07-18 MX MX2008000899A patent/MX2008000899A/es active IP Right Grant
- 2006-07-19 PE PE2006000870A patent/PE20070214A1/es not_active Application Discontinuation
- 2006-07-19 TW TW095126415A patent/TWI406661B/zh active
2007
- 2007-12-17 IL IL188189A patent/IL188189A0/en unknown
2008
- 2008-01-09 MA MA30566A patent/MA29626B1/fr unknown
- 2008-01-11 CR CR9657A patent/CR9657A/es not_active Application Discontinuation
- 2008-01-17 CU CU2008000006A patent/CU23916B1/es active IP Right Grant
- 2008-01-18 EC EC2008008119A patent/ECSP088119A/es unknown
- 2008-01-18 TN TNP2008000029A patent/TNSN08029A1/en unknown
- 2008-02-14 NO NO20080820A patent/NO341930B1/no unknown
- 2008-02-26 HN HN2008000311A patent/HN2008000311A/es unknown
2011
- 2011-05-04 AU AU2011202047A patent/AU2011202047A1/en not_active Withdrawn
- 2011-08-15 IL IL214659A patent/IL214659A0/en unknown
2012
- 2012-03-09 AU AU2012201453A patent/AU2012201453C1/en active Active
- 2012-08-03 US US13/565,913 patent/US8415363B2/en active Active
- 2012-08-24 CY CY20121100769T patent/CY1113076T1/el unknown
- 2012-10-18 JP JP2012231108A patent/JP5798101B2/ja active Active
2013
- 2013-02-22 US US13/774,433 patent/US8829015B2/en active Active
- 2013-07-26 PH PH12013501590A patent/PH12013501590A1/en unknown
2014
- 2014-08-01 US US14/449,446 patent/US20140343087A1/en not_active Abandoned
- 2014-08-04 JP JP2014159022A patent/JP2014221831A/ja active Pending
2016
- 2016-03-17 JO JOP/2016/0047A patent/JO3308B1/ar active
2017
- 2017-04-24 HR HRP20170634TT patent/HRP20170634T4/hr unknown
- 2017-04-26 CY CY20171100471T patent/CY1119624T1/el unknown

Also Published As

Publication number	Publication date
AU2006276204A1 (en)	2007-02-08
TNSN08029A1 (en)	2009-07-14
CA2614334A1 (en)	2007-02-08
MY148554A (en)	2013-04-30
UA94234C2 (uk)	2011-04-26
NO20080820L (no)	2008-04-15
US20080269269A1 (en)	2008-10-30
EP2284167A3 (en)	2011-03-02
EA016856B1 (ru)	2012-08-30
WO2007015870A2 (en)	2007-02-08
IL214659A0 (en)	2011-09-27
PT2284167T (pt)	2017-05-15
EP2284168A2 (en)	2011-02-16
SG163620A1 (en)	2010-08-30
AU2011202047A1 (en)	2011-05-26
EP2284168A3 (en)	2011-04-13
GEP20115302B (en)	2011-10-10
SI1912973T1 (sl)	2012-08-31
PL2284167T5 (pl)	2020-07-27
ES2623608T5 (es)	2020-06-18
EP2284167B1 (en)	2017-02-01
SMAP200800011A (it)	2008-02-27
TW200740793A (en)	2007-11-01
EP2543665A3 (en)	2013-05-29
JO3308B1 (ar)	2018-09-16
ES2386974T3 (es)	2012-09-10
SI2284167T1 (sl)	2017-05-31
US20130165465A1 (en)	2013-06-27
NZ564409A (en)	2011-07-29
HRP20170634T4 (hr)	2020-02-07
TWI406661B (zh)	2013-09-01
EP1912973A2 (en)	2008-04-23
AU2012201453A1 (en)	2012-04-05
PE20070214A1 (es)	2007-04-02
HUE031791T2 (en)	2017-08-28
JP2013018789A (ja)	2013-01-31
HRP20170634T1 (hr)	2017-06-30
CY1119624T1 (el)	2018-04-04
MX2008000899A (es)	2008-03-18
AR054846A1 (es)	2007-07-18
US20140343087A1 (en)	2014-11-20
KR20130085444A (ko)	2013-07-29
CU20080006A7 (es)	2011-02-24
PL1912973T3 (pl)	2012-09-28
DK2284167T3 (en)	2017-05-01
GT200600315A (es)	2007-03-19
PH12013501590A1 (en)	2015-09-21
KR101651288B1 (ko)	2016-08-25
BRPI0613615B1 (pt)	2022-02-08
KR20130077915A (ko)	2013-07-09
CN102358736A (zh)	2012-02-22
WO2007015870A3 (en)	2007-06-07
EA013464B1 (ru)	2010-04-30
RS55929B2 (sr)	2020-12-31
DK2284167T4 (da)	2020-03-02
EP2284167B2 (en)	2019-11-27
HK1116783A1 (en)	2009-01-02
EA201000145A1 (ru)	2010-06-30
ES2648288T3 (es)	2017-12-29
EP2535337B1 (en)	2017-08-23
DK1912973T3 (da)	2012-07-23
IL188189A0 (en)	2008-03-20
EP2543665A2 (en)	2013-01-09
SMP200800011B (it)	2008-02-27
US8415363B2 (en)	2013-04-09
AU2012201453C1 (en)	2024-05-23
CN103804356A (zh)	2014-05-21
JP5289948B2 (ja)	2013-09-11
BRPI0613615A2 (pt)	2011-01-18
CA2614334C (en)	2015-04-21
ECSP088119A (es)	2008-02-20
KR20080027853A (ko)	2008-03-28
SI2284167T2 (sl)	2020-03-31
US8343984B2 (en)	2013-01-01
RS55929B1 (sr)	2017-09-29
AU2012201453B2 (en)	2013-09-05
EP1912973B1 (en)	2012-06-13
JP2009502795A (ja)	2009-01-29
US20130023548A1 (en)	2013-01-24
NI200800017A (es)	2009-03-03
US8829015B2 (en)	2014-09-09
JP5798101B2 (ja)	2015-10-21
HN2008000311A (es)	2011-01-24
PT1912973E (pt)	2012-09-03
EP2535337A1 (en)	2012-12-19
JP2014221831A (ja)	2014-11-27
MA29626B1 (fr)	2008-07-01
EA200800201A1 (ru)	2008-06-30
NO341930B1 (no)	2018-02-19
CY1113076T1 (el)	2016-04-13
LT2284167T (lt)	2017-04-25
CR9657A (es)	2008-04-16
ES2623608T3 (es)	2017-07-11
PL2284167T3 (pl)	2017-07-31
EP2284167A2 (en)	2011-02-16
CU23916B1 (es)	2013-07-31

Publication	Publication Date	Title
HRP20170634T4 (hr)	2020-02-07	Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
JP2009502795A5 (sr)	2009-09-03
TW200633712A (en)	2006-10-01	Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
SG170772A1 (en)	2011-05-30	Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
IL187208A0 (en)	2008-02-09	Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
BRPI0507617A (pt)	2007-07-03	antagonistas de receptor de quimiocina
WO2006062981A3 (en)	2007-02-22	Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
NZ594597A (en)	2014-02-28	Substituted piperidines as ccr3 antagonists
UA94833C2 (en)	2011-06-10	Substituted bicyclolactams
CY1108713T1 (el)	2014-04-09	Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1)
CR9214A (es)	2007-11-23	2-fenilindoles como antagonistas del receptor de la prostaglandina d2
WO2006124692A3 (en)	2007-04-12	3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
DE602008002934D1 (de)	2010-11-18	2-cyclopropylthiazolderivate
MX2009007482A (es)	2009-08-13	Agentes antiparasitarios.
EP1630157A4 (en)	2007-05-23	ANTAGONIST OF CASR
UA94606C2 (ru)	2011-05-25	Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MX2009011579A (es)	2009-11-11	Pirimidinonas como moduladores de caseina cinasa ii (ck2).
DE602008001983D1 (de)	2010-09-09	Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
WO2008007251A3 (en)	2008-08-21	Antifungal compositions containing the endophyte fungus alternaria alternata and,or its metabolites, as antagonist agents of plasmopara viticola
GB0510584D0 (en)	2005-06-29	Organic compounds
DK2178858T3 (da)	2012-03-19	Nye heterocycliske forbindelser som mGlu5-antagonister
MX2007007100A (es)	2007-06-22	Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
TW200716597A (en)	2007-05-01	Novel piperidine-substituted indoles
AR063006A1 (es)	2008-12-23	Modificacion cristalina de 4-{[(6-cloropiridin-3-il)metil](metil)amino}furan-2(5h)-ona